JAHA:慢阻肺患者SAVR和SAVR该如何选择?

2018-04-02 MedSci MedSci原创

慢性阻塞性肺疾病(COPD)患者在心脏手术后发生呼吸相关性并发症的风险更高。目前对于COPD患者,经导管主动脉瓣置换术(TAVR)和外科主动脉瓣置换术(SAVR)哪个预后更佳尚不清楚。本研究纳入了数据库中2011年至2014年年龄≥60岁,接受了TAVR或SAVR治疗的COPD患者,最终共纳入了相互匹配的1210名TAVR患者和1208名SAVR患者。分析结果显示,相比于接受SAVR患者,接受TA

慢性阻塞性肺疾病(COPD)患者在心脏手术后发生呼吸相关性并发症的风险更高。目前对于COPD患者,经导管主动脉瓣置换术(TAVR)和外科主动脉瓣置换术(SAVR)哪个预后更佳尚不清楚。

本研究纳入了数据库中2011年至2014年年龄≥60岁,接受了TAVR或SAVR治疗的COPD患者,最终共纳入了相互匹配的1210名TAVR患者和1208名SAVR患者。分析结果显示,相比于接受SAVR患者,接受TAVR的患者发生气道造口术(0.8% vs 5.8%; [OR], 0.14; P<0.001)、急性呼吸衰竭(16.4% vs 23.7%; OR, 0.63; P=0.002)、重插管(6.5% vs 10.0%; OR, 0.49; P<0.001)和肺炎(4.5% vs 10.1%; OR, 0.41; P<0.001)的风险要明显降低,无创机械通气的使用率在两组间无明显差异。此外,非呼吸相关的并发症如院内死亡率、急性肾损伤和急性心梗的发生率在TAVR组中也明显更低。

研究结果显示,对于慢性阻塞性肺疾病患者,经导管主动脉瓣置换术的术后并发症发生率要明显低于外科主动脉瓣置换术,TAVR可能是个更好的选择。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086323, encodeId=50ce2086323fd, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Mon Jul 23 14:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267781, encodeId=6e7d126e7811b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 04 00:26:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531290, encodeId=06881531290d0, content=<a href='/topic/show?id=f748159211d' target=_blank style='color:#2F92EE;'>#SAVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15921, encryptionId=f748159211d, topicName=SAVR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713e12248174, createdName=Smile2684, createdTime=Wed Apr 04 00:26:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302052, encodeId=5d7730205259, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Apr 02 12:28:45 CST 2018, time=2018-04-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086323, encodeId=50ce2086323fd, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Mon Jul 23 14:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267781, encodeId=6e7d126e7811b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 04 00:26:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531290, encodeId=06881531290d0, content=<a href='/topic/show?id=f748159211d' target=_blank style='color:#2F92EE;'>#SAVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15921, encryptionId=f748159211d, topicName=SAVR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713e12248174, createdName=Smile2684, createdTime=Wed Apr 04 00:26:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302052, encodeId=5d7730205259, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Apr 02 12:28:45 CST 2018, time=2018-04-02, status=1, ipAttribution=)]
    2018-04-04 仁者大医
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086323, encodeId=50ce2086323fd, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Mon Jul 23 14:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267781, encodeId=6e7d126e7811b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 04 00:26:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531290, encodeId=06881531290d0, content=<a href='/topic/show?id=f748159211d' target=_blank style='color:#2F92EE;'>#SAVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15921, encryptionId=f748159211d, topicName=SAVR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713e12248174, createdName=Smile2684, createdTime=Wed Apr 04 00:26:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302052, encodeId=5d7730205259, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Apr 02 12:28:45 CST 2018, time=2018-04-02, status=1, ipAttribution=)]
    2018-04-04 Smile2684
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086323, encodeId=50ce2086323fd, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Mon Jul 23 14:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267781, encodeId=6e7d126e7811b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 04 00:26:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531290, encodeId=06881531290d0, content=<a href='/topic/show?id=f748159211d' target=_blank style='color:#2F92EE;'>#SAVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15921, encryptionId=f748159211d, topicName=SAVR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=713e12248174, createdName=Smile2684, createdTime=Wed Apr 04 00:26:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302052, encodeId=5d7730205259, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Apr 02 12:28:45 CST 2018, time=2018-04-02, status=1, ipAttribution=)]
    2018-04-02 yfjms

    学习

    0

相关资讯

Semin Arthritis Rheu:类风湿性关节炎、银屑病关节炎和银屑病预测心脏事件的心血管危险因素

女性RA患者和银屑病的额外心血管风险升高,而不是PsA。RA的全身炎症指标较高,而不是银屑病,表明这些病存在不同的心血管风险介质。

JACC:收缩压与急性主动脉夹层患者死亡率明显相关

收缩压(SBP)在许多心血管疾病中是一个预测患者死亡风险的有力工具。本研究的目的旨在评估SBP在预测急性主动脉夹层(AAD)患者的院内预后尤其是全因死亡率方面的作用。本研究纳入了数据库中6238名AAD患者(4167名患者为A型AAD,2071名为B型AAD),并根据患者的SBP分成4组:SBP >150, SBP 101 - 150, SBP 81 - 100和SBP ≤80 mm Hg。

Diabetes Care:收缩压对2型糖尿病患者心血管结局的影响!

由此可见,该研究结果支持将收缩压的治疗目标值设为140mmHg,并且怀疑无并发症的2型糖尿病患者更低的收缩压目标值(<120或130mmHg)CVD风险会降低。还需要一个随机对照试验来证实这些发现。

NEJM:非布司他或别嘌呤醇对痛风患者的心血管安全性分析!

由此可见,对于痛风合并主要心血管的患者,非布索坦的不良心血管事件发生率并不逊于别嘌呤醇。但是非布索坦的全因死亡率和心血管死亡率高于别嘌呤醇。

JAHA:冠心病发病率竟与出生地有关?!

在国外出生的美国成年人的比例逐年增加,然而心血管疾病的发生是否与出生地点相关仍属未知。本研究的目的旨在评估比较不同地方出生的美国人的冠心病(CHD)和卒中发病率。本研究纳入了2006年至2014年国家健康调查的数据,将出生地分成美国和其他国家,其他国家又分成6大地区。分析结果发现,在美国的成年人中,16%是在其他国家出生的,与出生在其他国家的成年人相比,出生在美国的年龄标准化后的CHD发病率和卒中

JACC:传统外科生物瓣膜置换术 vs 快速瓣膜释放术

目前,对于主动脉瓣疾病的患者,外科的传统生物瓣膜置换(CBVs)手术是治疗的标准,但是近期也出现了新式的快速释放瓣膜(RDVs)手术。本研究的目的旨在评估和比较RDVs和CBVs在治疗主动脉瓣狭窄患者中的疗效。本研究纳入了数据库中2011年至2015年接受外科主动脉瓣置换术(RDVs或者CBVs)的22062名患者,并通过1:1的倾向评分匹配比较了RDVs和CBVs患者的各类参数。最终共有2093